Sobi announces agreement with Enable Injections
Av The agreement, which applies to all of Sobi's markets, means that the enFuse injector from Cincinnati-based Enable will be used for the subcutaneous administration of pegcetacoplan, a drug developed by Sobi for the rare blood disease paroxysmal nocturnal hemoglobinuria (PNH).
The enFuse injector is designed to make self-administration more convenient. It is a technology that allows wearable, hidden needle drug delivery through a simple injection under the skin
– We believe the agreement with Enable will potentially expand patient choice, enhance comfort and support adherence, with the ultimate aim of better health outcomes. By continually improving the patient experience, we are working to make a meaningful difference in the lives of those we serve, said Lydia Abad-Franch, Head of R&D, Medical Affairs, and Chief Medical Officer at Sobi, in a press release.
Pegcetacoplan, with the brand names Aspaveli and Empaveli, is approved for the treatment of paroxysmal nocturnal hemoglobinuria in the US, EU and several other markets worldwide. It is a treatment that aims to regulate excessive activation of the complement cascade, part of the body's immune system, which can lead to the onset and progression of many serious diseases.
The treatment is also being evaluated for other rare diseases in hematology and nephrology.
Artikeln är en del av vårt tema om News in English.